Timing of postpartum enoxaparin administration and severe postpartum hemorrhage

被引:17
作者
Freedman, Rachel A. [1 ]
Bauer, Kenneth A. [2 ]
Neuberg, Donna S. [3 ]
Zwicker, Jeffrey I. [2 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA
[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol, Boston, MA 02215 USA
[3] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
关键词
enoxaparin; low-molecular-weight heparin; postpartum hemorrhage;
D O I
10.1097/MBC.0b013e3282f185dd
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The appropriate time to restart anticoagulation in the postpartum period is not known. The purpose of the present study was to determine whether the timing of postpartum enoxaparin influences hemorrhagic outcomes. A total of 95 women were treated with peripartum enoxaparin and compared with 303 consecutive deliveries where anticoagulation was not administered. The overall rate of severe postpartum hemorrhage did not differ significantly for women treated with peripartum enoxaparin (4.2%) versus nonanticoagulated control individuals (2.0%, P=0.40) nor for the subgroup of women who underwent vaginal delivery (3.6 versus 1.4%, P=0.55) or cesarean section (5.1 versus 3.4%, P=0.98). We did not observe any severe hemorrhagic events attributable to administration of postpartum enoxaparin. The first dose of enoxaparin was administered less than 24 h following delivery in 75% of vaginal deliveries and in 49% of cesarean sections where enoxaparin was given in the postpartum period. Two incisional hematomas were observed in the group of women who received enoxaparin within 24 h following cesarean section. Severe postpartum hemorrhage is an infrequent complication when enoxaparin is administered to hemostatically intact women between 5 and 24 h following a vaginal delivery or 12 - 36 h following cesarean section.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 19 条
[1]  
*AM COLL OBST GYN, 2002, INT J GYNECOL OBSTET, V79, P299
[2]   Postpartum haemorrhage in nulliparous women:: incidence and risk factors in low and high risk women -: A Dutch population-based cohort study on standard (≥500 ml) and severe (≥1000 ml) postpartum haemorrhage [J].
Bais, JMJ ;
Eskes, M ;
Pel, M ;
Bonsel, GJ ;
Bleker, OP .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2004, 115 (02) :166-172
[3]   Use of antithrombotic agents during pregnancy [J].
Bates, SA ;
Greer, IA ;
Hirsh, J ;
Ginsberg, JS .
CHEST, 2004, 126 (03) :627S-644S
[4]   A randomised double-blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thrombolic events after caesarean section: a pilot study [J].
Burrows, RF ;
Gan, ET ;
Gallus, AS ;
Wallace, EM ;
Burrows, EA .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2001, 108 (08) :835-839
[5]  
COMBS CA, 1991, OBSTET GYNECOL, V77, P77
[6]  
COMBS CA, 1991, OBSTET GYNECOL, V77, P69
[7]  
COMBS CA, 1991, OBSTET GYNECOL, V77, P863
[8]   Use of low-molecular-weight heparin from the first trimester of pregnancy: A retrospective study of 111 consecutive pregnancies [J].
Deruelle, Philippe ;
Denervaud, Muriel ;
Hachulla, Eric ;
Ducloy-Bouthors, Anne-Sophie ;
Valat, Anne-Sylvie ;
Puech, Francis ;
Trillot, Nathalie ;
Hatron, Pierre-Yves ;
Subtil, Damien .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2006, 127 (01) :73-78
[9]   Low-molecular-weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies [J].
Dulitzki, M ;
Pauzner, R ;
Langevitz, P ;
Pras, M ;
Many, A ;
Schiff, E .
OBSTETRICS AND GYNECOLOGY, 1996, 87 (03) :380-383
[10]   Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy [J].
Greer, IA ;
Nelson-Piercy, C .
BLOOD, 2005, 106 (02) :401-407